Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Liminatus Pharma ( (LIMN) ) has provided an announcement.
On June 24, 2025, Liminatus Pharma announced advancements in its research development programs, particularly with IBA101, a novel CD47 inhibitor. The company has completed pivotal studies and is preparing for regulatory submissions in the U.S. and Korea, with clinical trials expected to start in 2027. This development could significantly enhance Liminatus’s position in the immunotherapy market by offering a safer and more effective cancer treatment option. Additionally, Liminatus is exploring the potential of IBA101 in treating chronic inflammatory diseases, which could further expand its market reach.
More about Liminatus Pharma
Liminatus Pharma is a preclinical-stage immuno-oncology company focused on developing next-generation immunotherapies. The company is advancing IBA101, a CD47 checkpoint inhibitor, aimed at enhancing immune response while minimizing side effects like anemia and thrombocytopenia. Liminatus is leveraging its Nasdaq listing and strategic partnerships to position itself in the competitive cancer therapy market.
Average Trading Volume: 301,370
Technical Sentiment Signal: Buy
Current Market Cap: $375.4M
For a thorough assessment of LIMN stock, go to TipRanks’ Stock Analysis page.